Imaging has predictive value for bone cancer, data show

02/15/2014 | Healio (free registration)

Data suggest that FDG-PET tumor uptake may be used to predict how patients with bone sarcoma will respond to chemotherapy. All 65 patients with either bone sarcoma or soft-tissue sarcoma underwent PET imaging before doxorubicin-based neoadjuvant chemotherapy. Scans were collected again after two rounds of chemotherapy and ahead of surgery. Researchers found that tumor size, percentage change in SUVmax and tumor type had predictive value for patient survival, according to the study in The Journal of Bone & Joint Surgery.

View Full Article in:

Healio (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park